You searched for: dopaminerġika (Maltesiska - Engelska)

evidenza newrofarmakoloġika tissuġġerixxi l-involviment tas-sistema dopaminerġika primarja.
neuropharmacological evidence suggests primary dopaminergic system involvement.

safinamide jaġixxi kemm permezz ta’ mekkaniżmi ta’ azzjoni dopaminerġika kif ukoll mhux dopaminerġika.
safinamide acts through both dopaminergic and non-dopaminergic mechanisms of action.

marda ta ’ parkinson ikkurati b’ agonisti ta ’ dopamine u kura dopaminerġika oħra bħal stalevo.
disease patients treated with dopamine agonists and other dopaminergic treatments such as stalevo.

marda ta ’ parkinson ikkurati b’ agonisti ta ’ dopamine u kura dopaminerġika dopaminerġiċi oħra bħal stalevo.
disease patients treated with dopamine agonists and other dopaminergic treatments such as stalevo.

bil- marda ta ’ parkinson ikkurati b’ agonisti ta ’ dopamine u kura dopaminerġika oħra bħal stalevo.
disease patients treated with dopamine agonists and other dopaminergic treatments such as stalevo.

doża eċċessiva ta’ levodopa tista’ tagħti lok għal kumplikazzjonijiet sistemiċi, sekondarji għas-simulazzjoni żejda dopaminerġika.
levodopa overdose may give rise to systemic complications, secondary to dopaminergic overstimulation.

tqallih, relatat ukoll ma ’ attività dopaminerġika ċentrali msaħħa, huwa reazzjoni avversa komuni ta ’ levodopa/ carbidopa.
nausea, also related to enhanced central dopaminergic activity, is a common adverse reaction of levodopa/ carbidopa.

aripiprazole wera proprjetajiet antagonisti f’mudelli ta’ annimali ta’ attività dopaminerġika eċċessiva u proprjetajiet agonisti ta’ ipoattività dopaminerġika.
aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties of dopaminergic hypoactivity.

20 każijiet iżolati ta ’ nms ġew irrappurtati wara t- tnaqqis f’ daqqa jew wara l- waqfien ta ’ entacapone u kura dopaminerġika oħra.
isolated cases of nms have been reported following the abrupt reduction or discontinuation of entacapone and other dopaminergic treatments.

it-twaqqif f’daqqa tat-terapija dopaminerġika jista’ jwassal għall-iżvilupp tas-sindrome malinn newroleptiku.
abrupt discontinuation of dopaminergic therapy can lead to the development of a neuroleptic malignant syndrome.

sindrome malinn newroleptiku sintomi li jissuġġerixxu sindrome malinn newroleptiku kienu rrappurtati mat- twaqqif f’ daqqa tat - terapija dopaminerġika (ara sezzjoni 4. 2).
neuroleptic malignant syndrome symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy (see section 4.2.).